Dark

EBS
Emergent Biosolutions, Inc.
stock NYSE

At Close

May 9, 2025 3:59:55 PM EDT

5.65USD-11.164%(-0.71)1,969,619

5.64Bid 5.67Ask 0.03Spread

Pre-market

May 9, 2025 9:25:30 AM EDT

6.32USD-0.629%(-0.04)6,201

After-hours

May 9, 2025 4:05:30 PM EDT

5.66USD+0.177%(+0.01)1,045

OverviewOptionsHistoricalExchangesShortsNews

Jan 14, 2022

06:42AM EST Emergent BioSolutions Says Fuad El-Hibri, Founder And Executive Chairman, Will Retire Effective April 1, 2022 RTTNews

06:30AM EST Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022. GlobeNewswire Inc

Jan 9, 2022

05:03PM EST Emergent BioSolutions Sees FY 2021 Revenue $1.78B vs $1.7B Est, Inline With Prior Guidance; See FY 2022 Revenue $1.45B vs $1.44B Est Benzinga

02:00PM EST Emergent BioSolutions Announces 2022 Financial Guidance, Provides GlobeNewswire Inc

Jan 3, 2022

06:30AM EST Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the companys executive management team will participate in the following investor conferences in the first quarter of 2022: GlobeNewswire Inc

Dec 16, 2021

07:37AM EST Emergent BioSolutions Doses First Patient In Phase 1 Study Of Universal Influenza Vaccine Candidate RTTNews

07:34AM EST Emergent BioSolutions Announces Initiation Of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate Benzinga

07:30AM EST Emergent BioSolutions Announces Initiation of Phase 1 Study GlobeNewswire Inc

Nov 24, 2021

02:00PM EST Johnson & Johnson's COVID-19 Shot Wins Its First Full Approval In Canada Benzinga

Nov 22, 2021

06:01PM EST SiTime Set to Join S&P MidCap 400; Emergent BioSolutions to Join S&P SmallCap PR Newswire

05:25PM EST S&P Dow Jones Indices Announces SiTime Will Join S&P MidCap 400, Emergent To Joint S&P SmallCap 600 Benzinga

Nov 12, 2021

07:47AM EST The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares Benzinga

Nov 11, 2021

04:22PM EST Emergent BioSolutions Reports $250M Buyback Benzinga

04:05PM EST Emergent BioSolutions Inc.(NYSE: EBS) today announced that its Board of Directors has authorized management to repurchase up to$250 millionof the company's common stock from time to time on the open market or in privately negotiated transactions. This repurchase authorization expires on November 11, 2022. GlobeNewswire Inc

Nov 10, 2021

08:24AM EST Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $75 Benzinga

Nov 9, 2021

10:52AM EST Watching Emergent BioSolutions; Hearing Benchmark Downgrades To Hold Benzinga

Nov 8, 2021

09:06AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 Benzinga

06:53AM EST Benchmark Downgrades Emergent BioSolutions to Hold Benzinga

Nov 5, 2021

02:57PM EDT Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher Benzinga

12:35PM EDT Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet Benzinga

10:23AM EDT Maryland-based healthcare company, Emergent BioSolutions Inc. (EBS), is trading 32% lower in the Friday market on news of termination of a government deal. RTTNews

09:43AM EDT The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill Benzinga

09:32AM EDT Emergent BioSolutions Q3 EPS $(0.36) Down From $2.19 YoY, Sales $329.00M Miss $486.84M Estimate Benzinga

Nov 4, 2021

08:19AM EDT The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO Benzinga

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 2, 2021

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. GlobeNewswire Inc

Oct 31, 2021

02:24PM EDT The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline Benzinga

Oct 28, 2021

12:20PM EDT Millions Of JNJ COVID-19 Shots Sit Idle At Emergent's Baltimore Plant: Reuters Benzinga

06:24AM EDT Reuters Reported 30M to 50M Doses of Johnson & Johnson's Covid-19 Vaccine Stored in Emergent Biosolutions' Plant in Baltimore Awaiting Green Light from U.S. Regulators to Ship Benzinga

Oct 18, 2021

06:30AM EDT Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial results for the third quarter of 2021, recent business developments, and financial outlook for full year 2021. GlobeNewswire Inc

Oct 15, 2021

07:44AM EDT The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO Benzinga

06:46AM EDT Emergent BioSolutions Begins Phase 3 Study Of Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP RTTNews

06:31AM EDT Emergent BioSolutions Reports Initiation Of Pivotal Phase 3 Trial Evaluating Safety, Immunogenicity Of Its Chikungunya Vaccine Candidate, CHIKV VLP Benzinga

06:30AM EDT Emergent BioSolutions Announces Initiation of Pivotal Phase 3 GlobeNewswire Inc

Oct 11, 2021

10:50AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 22, 2021

07:45AM EDT The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs Benzinga

Sep 21, 2021

01:23PM EDT Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc. Business Wire

Sep 14, 2021

10:34AM EDT Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate Benzinga

08:00AM EDT -- Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021 GlobeNewswire Inc

07:59AM EDT Emergent BioSolutions Secures Multi-Year Development And Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B Benzinga

Aug 26, 2021

12:35AM EDT Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns Benzinga

12:34AM EDT Moderna Withdraws Over 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns Benzinga

Aug 25, 2021

09:03AM EDT Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment Benzinga

06:34AM EDT Emergent BioSolutions' COVID-19 Human Immune Globulin Product Candidate To Be Evaluated In NIH-Sponsored Phase 3 Clinical Trial Of Hyperimmune Intravenous Immunoglobulin For Outpatient Treatment Of COVID-19 Benzinga

06:30AM EDT -- NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergents COVID-19 Human Immune Globulin (COVID-HIG), for potential treatment of COVID-19 in adult patients at risk of progression to severe disease GlobeNewswire Inc

Aug 23, 2021

04:05PM EDT Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the companys senior management team will participate in the following investor conferences: GlobeNewswire Inc

Jul 30, 2021

11:32AM EDT UPDATE: Chardan On Emergent BioSolutions Post-Earnings: Firm Highlights FDA Allowing Co. To Resume Production Of JNJ Covid-19 Vaccine Bulk Substance At Bayview; Projects Co. To Generate Cash Flow From Operations In 2021 At $446M Benzinga

11:32AM EDT Chardan Research Maintains Buy Rating On Emergent BioSolutions Inc. With $92 Price Target Benzinga

10:07AM EDT From Emergent BioSolutions Earlier 10-Q Filing: Co. Says Department Of Justice, Financial Industry Regulatory Authority, Securities And Exchange Commission, Others Have Sent Inquiries, Subpoenas Benzinga

10:06AM EDT From Emergent BioSolutions Earlier 10-Q Filing: Co. Says Has Received Inquiries, Subpoenas From U.S. Authorities To Produce Documents Related To Capabilities To Manufacture COVID-19 Vaccine Bulk Drug Substance Benzinga

Jul 29, 2021

05:16PM EDT Emergent Biosolutions Says Expects To Begin Late Stage Study In Partnership With U.S. Government Of COVID-19 Therapy Candidate In Near Term Benzinga

05:11PM EDT Emergent Biosolutions Says Working With AstraZeneca On Documentation For U.S. Government COVID-19 Vaccine Dose Shipments Benzinga

04:33PM EDT Emergent Biosolutions Reaffirms FY21 Total Sales $1.7B-$1.9B vs $1.8B Estimate, Adj. Net Income $395M-$470M, Adj. EBITDA $620M-$720M Benzinga

04:32PM EDT Emergent BioSolutions Q2 EPS $0.33 Down From $1.98 YoY, Sales $397.50M Miss $398.93M Estimate Benzinga

10:16AM EDT Emergent BioSolutions Stock Higher As COVID-19 Vaccine Production To Resume At Baltimore Plant Benzinga

08:18AM EDT The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs Benzinga

08:04AM EDT Emergent BioSolutions To Resume Manufacturing COVID-19 Vaccine At Bayview Facility Benzinga

07:25AM EDT Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at GlobeNewswire Inc

04:23AM EDT Earnings Scheduled For July 29, 2021 Benzinga

Jul 26, 2021

09:01AM EDT Reverse the Silence Campaign Casts a National Spotlight on GlobeNewswire Inc

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 23, 2021

04:40PM EDT These Companies Have Seen Large Returns From 2020 Government Investment Benzinga

Jul 15, 2021

06:30AM EDT Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial results for the second quarter of 2021, recent business developments, revenue guidance for the third quarter of 2021, and financial outlook for full year 2021. GlobeNewswire Inc

Jul 6, 2021

06:53AM EDT FDA Releases More JNJ's COVID-19 Vaccine Substance From Baltimore Plant Benzinga

Jul 2, 2021

03:24PM EDT UPDATE: FDA Says Is Not Yet Ready To Include The Emergent Biosolutions Plant In Janssen EUA As An Authorized Manufacturing Plant Benzinga

03:24PM EDT FDA Says Concluded These Batches Manufactured At Emergent Facility Are Suitable For Use; Says Conducted Thorough Review Of Facility, Results Of Quality Testing Performed By Manufacturer Benzinga

03:23PM EDT FDA Says Authorized Use, Under EUA For Janssen COVID-19 Vaccine, Of An Additional Batch Of Vaccine Drug Substance Manufacturing At Emergent Facility Benzinga

Jun 28, 2021

10:27AM EDT A Look Into Healthcare Sector Value Stocks Benzinga

Jun 23, 2021

09:21AM EDT U.S. Congressional Investigators Expand Inquiry Into Emergent Biosolutions Amid COVID-19; 2 House Panels Seeking Details On Emergent's Relationship With AstraZeneca And Johnson & Johnson In Producing COVID-19 Vaccines Benzinga

Jun 21, 2021

10:18AM EDT 5 Value Stocks To Watch In The Healthcare Sector Benzinga

Jun 17, 2021

07:00PM EDT and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Emergent BioSolutions Inc. - EBS PR Newswire

09:06AM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

Jun 16, 2021

10:27PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 15, 2021

11:06PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

04:51PM EDT 3 Day Deadline Reminder: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

Jun 14, 2021

10:56PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

08:21PM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

11:05AM EDT EBS Deadline Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors or PR Newswire

Jun 12, 2021

12:06PM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

Jun 11, 2021

04:36PM EDT Emergent BioSolutions Saus Two Batches Of COVID-19 Vaccine Manufactured By Co. Were Determined Suitable For Use By FDA Benzinga

04:35PM EDT -- Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GlobeNewswire Inc

02:27PM EDT FDA Authorizes 10M JNJ COVID-19 Vaccine Doses, Asks To Discard 60M From Emergent Plant: NYT Benzinga

12:10PM EDT Investor Deadline Approaching: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

09:41AM EDT UPDATE: FDA Not Yet Expected To Fully Clear Emergent Biosolutions Facility In Baltimore, FDA Is Reviewing J&J COVID-19 Vaccine Doses In Batches Benzinga

09:40AM EDT FDA Preparing To Approve ~10M J&J COVID-19 Vaccines From Emergent Biosolutions' Baltimore Facility That Saw Contamination Benzinga

Jun 9, 2021

09:33PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 8, 2021

10:49PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

05:37PM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

02:52PM EDT Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. PR Newswire

Jun 7, 2021

11:14PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

07:19PM EDT EBS Investor Reminder: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

02:52PM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

Jun 4, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

Jun 3, 2021

06:07PM EDT Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of GlobeNewswire Inc

03:56PM EDT Entwistle & Cappucci LLP Announces It Has Filed a Securities Class Action Against Emergent BioSolutions Inc. (NYSE: EBS) Business Wire

08:33AM EDT AstraZeneca Seeks Switching COVID-19 Vaccine Production to Catalent Plant: NYT Benzinga

Jun 2, 2021

11:45PM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

09:59PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

12:55PM EDT Deadline in Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. PR Newswire

Jun 1, 2021

05:39PM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

May 31, 2021

10:16PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 30, 2021

01:00PM EDT EBS DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

May 28, 2021

04:24PM EDT Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class PR Newswire

11:37AM EDT Emergent BioSolutions Poised To Receive FDA Nod to Restart J&J COVID-19 Shot Production at Baltimore Plant After Mishap: WSJ Benzinga

May 27, 2021

02:50PM EDT Justice Department Opens Probe In Presumed lapses at Eli Lilly's COVID-19 Drug Plant: Reuters Benzinga

May 26, 2021

10:43PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

08:46PM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

04:08PM EDT INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Alerts GlobeNewswire Inc

08:48AM EDT Emergent BioSolutions's Single-Dose Chikungunya Vaccine Candidate Effective Even After Two Years of Vaccination Benzinga

07:30AM EDT Emergent BioSolutions Inc. (EBS) announced Wednesday positive two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of investigational chikungunya virus virus-like particle or CHIKV VLP vaccine candidate in 415 healthy adults. RTTNews

06:36AM EDT Emergent BioSolutions Reports Positive 2-Yr Persistence Data From Phase 2 Study On CHIKV VLP RTTNews

06:33AM EDT Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, The Company's Chikungunya Virus Virus-Like Particle Vaccine Candidate Benzinga

06:30AM EDT Emergent BioSolutions Announces Positive Two-Year Persistence Data GlobeNewswire Inc

May 25, 2021

10:00PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

May 24, 2021

11:10PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 23, 2021

11:50AM EDT DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in PR Newswire

11:05AM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

May 22, 2021

05:08PM EDT Investor Deadline Alert: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

May 21, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 20, 2021

09:53PM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

May 19, 2021

10:00PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:34AM EDT At U.S. House Hearing, Emergent CEO Says One Batch Ruined In March Was Roughly Equivalent To 15M Doses Of J&J Vaccine Benzinga

11:19AM EDT At U.S. House Hearing, Emergent CEO Says U.S. Government Failed To Provide Sufficient Support To Co Ahead Of Pandemic To Allow It To Reach Full Manufacturing Potential Benzinga

10:52AM EDT Emergent BioSolutions Stock Falls As Executives Face Questions As Part Of Botched Vaccine Probe Benzinga

May 18, 2021

10:56PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

07:08PM EDT Class Action Deadline Reminder: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

11:56AM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

08:01AM EDT Cramer Weighs In On Beyond Meat, Snowflake, More Benzinga

May 17, 2021

10:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

11:36AM EDT Against Emergent Biosolutions Inc. (NYSE: EBS) For Violations Of Federal Securities Laws With Expanded Class Period PR Newswire

May 14, 2021

10:50PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

May 13, 2021

01:41PM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

May 12, 2021

09:44PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

05:16PM EDT Emergent BioSolutions Inc. Investors of Securities Fraud Class Action Lawsuit PR Newswire

01:35PM EDT Emergent Initiates Quality Enhancement Plan For Troubled Baltimore Vaccine Facility Benzinga

01:01PM EDT Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of Emergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). If you are a shareholder of Emergent with more than $300,000 in losses, you should contact the Firm. GlobeNewswire Inc

09:35AM EDT Emergent BioSolutions Shares Quiet; Co's Executives To Testify In Congress May 19 Benzinga

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

08:39AM EDT Emergent BioSolutions Issues Response To FDA's Observations; Says Started Making Enhancements To Meet Or Exceed FDA Standards Benzinga

May 11, 2021

10:33PM EDT The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. GlobeNewswire Inc

May 10, 2021

11:24PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

04:44PM EDT FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic Benzinga

01:27PM EDT CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces GlobeNewswire Inc

May 8, 2021

11:41AM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

May 7, 2021

10:45PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

06:19PM EDT Investors of Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. PR Newswire

May 6, 2021

02:35PM EDT Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP GlobeNewswire Inc

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

06:30AM EDT Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 20, 2021 at 9:00 AM EDT. GlobeNewswire Inc

May 5, 2021

04:05PM EDT Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the companys senior management team will participate in the following investor conferences: GlobeNewswire Inc

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021 Benzinga

08:55AM EDT Argus Research Downgrades Emergent BioSolutions to Hold Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 3, 2021

11:00PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

09:52PM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

May 2, 2021

10:15AM EDT EBS EQUITY ALERT: Kessler Topaz Meltzer & Check, LLP Announces GlobeNewswire Inc

May 1, 2021

06:33PM EDT Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Lawsuit Filed PR Newswire

Apr 30, 2021

02:36PM EDT Emergent BioSolutions Has Supply Of 60M Johnson & Johnson COVID-19 Vaccine Doses Awaiting Approval: Bloomberg Benzinga

11:14AM EDT Emergent BioSolutions Hopeful To Restart Vaccine Production, Plans To Submit Response To FDA Within Days Benzinga

10:27AM EDT Chardan Capital Maintains Buy on Emergent BioSolutions, Lowers Price Target to $92 Benzinga

07:31AM EDT The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs Benzinga

Apr 29, 2021

05:03PM EDT Emergent BioSolutions: Q1 Earnings Insights Benzinga

04:42PM EDT Emergent BioSolutions Q1 EPS $1.53 Beats $1.12 Estimate, Sales $343.00M Miss $358.47M Estimate Benzinga

02:39PM EDT Emergent Biosolutions Says Has 60M Doses Of Johnson & Johnson COVID-19 Vaccine Awaiting Approval Benzinga

08:15AM EDT The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx Benzinga

04:10AM EDT Earnings Scheduled For April 29, 2021 Benzinga

Apr 28, 2021

10:59AM EDT A Preview Of Emergent BioSolutions's Earnings Benzinga

Apr 27, 2021

04:06PM EDT Investors with $100k+ Losses to Contact its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO's Insider Sales PR Newswire

Apr 26, 2021

10:48PM EDT Kahn Swick & Foti, LLC (KSF) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

07:42PM EDT Hagens Berman urges Emergent BioSolutions Inc. (NYSE: EBS) investors with $100k or more losses to submit your losses now. GlobeNewswire Inc

11:55AM EDT Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of PR Newswire

Apr 24, 2021

03:40PM EDT EBS ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of GlobeNewswire Inc

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

01:46AM EDT LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors to Contact PR Newswire

12:06AM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Apr 23, 2021

10:50PM EDT ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: GlobeNewswire Inc

03:03PM EDT FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training Benzinga

10:17AM EDT JNJ's COVID-19 Vaccine Halt Due To Blood-Clot Concerns To Be Scrutinized Today: WSJ Benzinga

Apr 22, 2021

08:09AM EDT The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs Benzinga

Apr 21, 2021

05:01PM EDT Securities Fraud Class Action Lawsuit Filed Against Emergent BioSolutions Inc. PR Newswire

12:47PM EDT Statement on Issuance of Form FDA 483 at Emergent Bayview Facility GlobeNewswire Inc

12:42PM EDT Emergent Biosolutions Says Shortcomings In Manufacturing Facilities Or Process Are Correctable, Will Take Swift Action To Remedy Them Benzinga

12:38PM EDT FDA's Inspection Of Emergent's COVID-19 Vaccine Baltimore Plant Outlines Concerns About Sanitary Conditions, Employee Training Benzinga

09:21AM EDT FDA Says Recently Completed Inspection Of Emergent Biosolutions' Proposed Manufacturing Facility For Johnson & Johnson Vaccine; Says Cited Number Of Observations Concerning Whether Facility's Processes Met Requirements And Standards Benzinga

07:52AM EDT House Democrats Investigating Emergent BioSolutions' Vaccine Contracts, Call On Execs To Testify Benzinga

07:31AM EDT The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue Benzinga

Apr 20, 2021

07:12PM EDT Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud GlobeNewswire Inc

12:12PM EDT EMA Finds Potential Blood Clot Link With JNJ COVID-19 Shot, Adds Safety Warning Benzinga

Apr 19, 2021

01:20PM EDT Emergent BioSolutions Stock Falls After FDA Initiates Inspection Of Bayview Facility Benzinga

12:40PM EDT Saxena White P.A. Files Securities Fraud Class Action Against GlobeNewswire Inc

06:25AM EDT Emergent BioSolution Announces The FDA Has Initiated An Inspection Of The Bayview Facility; Co. Reports ' Emergent will not to initiate the manufacturing of any new material at its Bayview facility and to quarantine existing material manufactured at the Bayview facility pending completion of the inspection' Benzinga

06:24AM EDT Emergent BioSolution Announces The FDA Has Initiated An Inspection Of The Bayview Facility; Co. Reports 'not to initiate the manufacturing of any new material at its Bayview facility and to quarantine existing material manufactured at the Bayview facility Benzinga

Apr 15, 2021

06:30AM EDT Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 29, 2021 at 5:00 pm eastern time to discuss the financial results for the first quarter of 2021, recent business developments, revenue guidance for the second quarter of 2021, and financial outlook for full year 2021. GlobeNewswire Inc

Apr 14, 2021

10:49PM EDT Pomerantz LLP is investigating claims on behalf of investors ofEmergent BioSolutions Inc. (Emergent or the Company) (NYSE: EBS). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Apr 9, 2021

11:51AM EDT Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded Benzinga

Apr 8, 2021

02:59PM EDT US Allocates Significantly Lower Number Of J&J Vaccines To States For Next Week: Reuters Benzinga

11:51AM EDT Entwistle & Cappucci LLP Investigative Alert: Emergent BioSolutions Inc. (EBS) Business Wire

Apr 7, 2021

07:37AM EDT Benchmark Initiates Coverage On Emergent BioSolutions with Buy Rating, Announces Price Target of $150 Benzinga

Apr 5, 2021

09:47AM EDT US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca Benzinga

07:14AM EDT Emergent BioSolutions' Plasma-Based Therapy Candidate Flunks COVID-19 Study; HHS Increases Task Order By $23M Benzinga

05:28AM EDT Emergent BioSolutions Reaffirmed its 2021 Financial Guidance Benzinga

05:27AM EDT Emergent BioSolutions Announced it's On Track with Respect to COVID-19 Contractual Commitments; Said it Received Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson's COVID-19 Vaccine Benzinga

02:38AM EDT Emergent BioSolutions: HHS Increases Task Order By $23 Mln RTTNews

Apr 4, 2021

10:09PM EDT -- HHS has increased Emergents task order by $23 million to purchase additional biologics manufacturing equipment -- Reaffirms 2021 financial guidance GlobeNewswire Inc

02:08PM EDT US Puts Johnson & Johnson In Charge Of Troubled Vaccine Plant In Baltimore, Removes AstraZeneca Benzinga

10:21AM EDT 15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT Benzinga

Apr 2, 2021

08:00AM EDT Emergent BioSolutions Announces Topline Data from NIAID Phase 3 GlobeNewswire Inc

Apr 1, 2021

04:33PM EDT Emergent CEO Says Does Not Expect Significant Delay In Getting FDA Approval For Bayview Plant Benzinga

02:23PM EDT Emergent Biosolutions Says Isolated Batch Of COVID-19 Drug Substance That Did Not Meet Specifications And It Will Be Disposed Of Properly Benzinga

09:59AM EDT Emergent BioSolutions Inc. (EBS) shares are sliding as Johnson and Johnson (JNJ) identified that one batch of drug substance for its COVID-19 vaccine at Emergent failed to meet quality standards. In an email statement, JNJ claimed that the batch was never part of the manufacturing process. RTTNews

05:52AM EDT 15M Doses Of JNJ COVID-19 Vaccine Batch Ruined After Ingredient Issues At Emergent Biosolutions' US Plant: NYT Benzinga

Mar 31, 2021

06:34PM EDT New York Times Corrects Earlier Report On Johnson & Johnson Vaccine; Says Mix-Up Only Halts 'Future Shipments' Of Vaccine And Does Not Affect Doses Currently Being Delivered Nationwide Benzinga

05:42PM EDT Hearing 'The Plant Is Run By Emergent BioSolutions, A Manufacturing Partner To Both Johnson & Johnson And AstraZeneca, Federal Officials Attributed The Mistake To Human Error' Benzinga

Mar 9, 2021

11:35AM EST New York Times Credits Report On Emergent BioSolutions For Biden's Canceled Vaccine Plant Visit Benzinga

Mar 1, 2021

06:30AM EST Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the companys senior management team will participate in the following investor conferences: GlobeNewswire Inc

Feb 24, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2021 Benzinga

07:22AM EST Chardan Capital Upgrades Emergent BioSolutions to Buy, Announces $112 Price Target Benzinga

Feb 19, 2021

10:57AM EST Looking Into Emergent BioSolutions's Return On Capital Employed Benzinga

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 19, 2021 Benzinga

08:06AM EST Chardan Capital Downgrades Emergent BioSolutions to Neutral, Announces $112 Price Target Benzinga

Feb 18, 2021

05:16PM EST From Emergent Biosolutions Earnings Conference Call: Vaccination, Development Of Effective Treatments Will Be Needed For Many Years To Come Benzinga

04:45PM EST Emergent BioSolutions: Q4 Earnings Insights Benzinga

04:29PM EST Emergent Reaffirms FY21 Guidance Benzinga

04:29PM EST Emergent BioSolutions Q4 Adj. EPS $3.67 Beats $3.19 Estimate, Sales $583.00M Beat $563.60M Estimate Benzinga

08:14AM EST The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout Benzinga

04:28AM EST Earnings Scheduled For February 18, 2021 Benzinga

Feb 4, 2021

06:30AM EST Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 18, 2021 at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2020, recent business developments, financial outlook for full year 2021, and revenue guidance for the first quarter of 2021. GlobeNewswire Inc

Jan 25, 2021

08:54AM EST Emergent, Humanigen Enter Contract Development And Manufacturing Services Agreement For Lenzilumab RTTNews

08:30AM EST Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab(tm) Business Wire

Jan 10, 2021

02:00PM EST Emergent BioSolutions Announces 2021 Financial Guidance, Provides GlobeNewswire Inc

Jan 8, 2021

10:04AM EST Benzinga's Top Upgrades, Downgrades For January 8, 2021 Benzinga

07:56AM EST Wells Fargo Downgrades Emergent BioSolutions to Equal-Weight Benzinga

Jan 4, 2021

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 29, 2020

04:06PM EST Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin Product Candidate for Prophylaxis Benzinga

04:05PM EST Emergent BioSolutions and Mount Sinai Health System Announce GlobeNewswire Inc

Dec 3, 2020

11:00AM EST Cramer Shares His Thoughts On Jumia, GrowGeneration And More Benzinga

Nov 13, 2020

07:51AM EST Benzinga Pro's Top 5 Stocks To Watch For Friday, Nov. 13, 2020: DKNG, ACM, BIDU, BOXL, EBS Benzinga

Nov 5, 2020

05:02PM EST Emergent BioSolutions Sees FY20 Sales $1.52B-$1.58B Vs $1.53B Estimates Benzinga

05:00PM EST Emergent BioSolutions Q3 EPS $2.19 Beats $2.12 Estimate, Sales $385.20M Miss $437.93M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 15, 2020

06:30AM EDT Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 5, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2020, recent business developments, revenue guidance for the fourth quarter of 2020, and financial outlook for full year 2020. GlobeNewswire Inc

Oct 13, 2020

09:47AM EDT Return On Capital Employed Overview: Emergent BioSolutions Benzinga